Complix to Present at Upcoming BioEquity Europe 2013: http://t.co/jzPUX0k7Bp
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
De Amerikaanse bedrijven Johnson & Johnson en FRX Polymers kregen gisteren de allereerste prijzen voor buitenlandse investeerders in Vlaanderen. Stijgende exportcijfers maakten het feestje compleet. read more
Mediconsult, the outsourcing division of Vandycke & Partners, the well-known recruitment agency in Healthcare, has made the list of Trends Gazelle companies 2013 for the third year running and has achieved one of its highest rankings thus far. The list is published annually and contains an overview of fastest growing companies in Belgium that enhance the competitive ability of a region and influence the entrepreneurial climate in a positive way. Making the list three consecutive years is very rare for any company. Mediconsult is thrilled with the award. read more
In het kmo‐land Vlaanderen is innoveren belangrijker dan ooit. Om deze innovatiegolf de aandacht te geven die het verdient, reikt het IWT voor de derde maal zijn IWT Innovatie Awards uit. Hiermee wil het IWT het belang van innovatie ook bij het brede publiek onder de aandacht brengen, en wil het de steun van de Vlaamse overheid aan innovatieve bedrijven onderstrepen. read more
On Monday 4 February, Dennis J. Selkoe and five other “brain teasers” will receive an honorary doctorate from the KU Leuven. The promoters for this honorary doctorate – VIB-KU Leuven professors Bart De Strooper and Wim Robberecht – will honor Dennis J. Selkoe for his scientific insights, but also for his relentless search for new medicines to treat Alzheimer’s Disease and other conditions that cause severe damage in the brain. read more
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that it won the Licensing Deal of the Year Award at the Scrip Awards 2012 event held in London last night. The Company received the global industry recognition for its partnership agreement with Alcon (Novartis) to commercialize JETREA® (ocriplasmin) outside the U.S. JETREA® is the first pharmacological treatment for vitreomacular adhesion (VMA), a progressive sight-threatening disease. JETREA® was recently approved by the U.S. Food and Drugs Administration for the treatment of symptomatic Vitreomacular Adhesion (VMA). The JETREA® European Marketing Authorisation Application is currently under review by the European Medicines Agency. A decision on European approval is expected in the first half of 2013. read more
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that JETREA® (ocriplasmin) has been selected to receive a Single Technology Appraisal (STA) from the UK’s National Institute for Health and Clinical Excellence (NICE). The outcome of the STA, in the form of NICE guidance, is expected later in 2013, following the launch of JETREA® in the UK. read more
ReGenesys, subsidiary of Athersys, Inc. (NASDAQ: ATHX) announced it recently received the BioProcess International Award for the “Technical Application of the Decade” in Manufacturing for its development of an automated bioreactor system for the production of MultiStem®, Athersys’ proprietary, off-the-shelf stem cell therapy. read more